Myllia Biotechnology

Myllia Biotechnology is redefining functional genomics by uniting CRISPR-based perturbations, single-cell resolution, and advanced computational modeling. Our platform integrates high-content CRISPR screens with single-cell RNA sequencing in primary human cells to deliver deeply physiologic, mechanistic insights. By generating large-scale, custom perturbation datasets, we enable AI-driven foundation models of virtual cells that infer causal relationships, reveal mechanisms of action, and accelerate unbiased target discovery. This end-to-end approach produces genetically validated, high-value targets for early-stage drug development and generates AI-ready data at a scale and fidelity previously impossible. The "High-Content CRISPR Screening" conference will take place from March 18-19, 2026, in Vienna, Austria. You can register and submit an abstract using the website link: